← Patent-cliff monitor small molecule CABOMETYX CABOZANTINIB S-MALATE
Loss of exclusivity July 2033 latest FDA-listed patent expiry
Company Exelixis → View the full company profile on CliffBio Drug detail Brand name CABOMETYX Active ingredient CABOZANTINIB S-MALATE Strength EQ 20MG BASE Dosage form TABLET Route ORAL Modality Small molecule FDA approval April 2016 Marketing status RX
Listed patents Patent Expires Type 9724342 July 2033 product 12128039 February 2032 product 11298349 February 2032 product 10039757 July 2031 use U-1480 10034873 July 2031 use U-2488 8877776 October 2030 substance, product 11098015 January 2030 use U-3225 11091440 January 2030 product 11091439 January 2030 substance 7579473 August 2026 substance, product
Regulatory exclusivity Code Expires ODE-530 March 2032 ODE-375 September 2028 ODE-227 January 2026
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.